Author(s)

Hardeep Sak

Affiliation(s)

Department of Chemistry, Career Point University, Tikker-Kharwarian, Hamirpur, Himachal Pradesh 17604, India.

Corresponding Author

Hardeep Sak

ABSTRACT

Complement is an important part of the immune system and plays an important role in the body's natural defense and immune regulation. Excessive activation of complement can cause inflammation and tissue damage. In particular, excessive activation of the alternative complement pathway plays an important role in the occurrence and development of a series of diseases and symptoms. Role. Cobra venom factor, a specific activating protein of the complement alternative pathway isolated from cobra venom, has played an important role in complement-related research use. Here is a review of the application of cobra venom factors in life sciences.

KEYWORDS

Cobra venom factor; Complement; Complement alternative pathway; Endothelial cells; Inflammation

CITE THIS PAPER

Hardeep Sak. Application of cobra venom factors in life sciences. Journal of Trends in Life Sciences. 2023, 1(2): 5-9. DOI:10.61784/jtls231223.

REFERENCES

[1] Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res, 2010, 20: 34-50

[2] Merle SH, Noah R, R, Halbwachs-Mecarelli L, L, et al. Complement system part II: role in immunity. Front Immunol, 2015, 6: 257

[3] Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov, 2010, 9: 43-56

[4] Ricklin D, Hajishengallis G, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol, 2010, 11: 785-97

[5] Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol, 2006, 176: 1305-10

[6] Holers VM. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev, 2008, 223: 300-16

[7] Ballow M, Cochrane CG. Two anticomplement factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. J Immunol, 1969, 103: 944-52

[8] Müller-Eberhard HJ, Fjellstrom KE. Isolation of the anticopmlementary protein from cobra venom and its mode of action on C3. J Immunol, 1971, 107: 1666-72

[9] Pepys MB, Tompkins C, Smith AD. An improved method for the isolation from Naja naja venom of cobra factor (CoF) free of phospholipase A. J Immunol Methods, 1979,30: 105-17

[10] von Zabern I, Hinsch B, Przyklenk H, et al. Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage. Immunobiology, 1980, 157: 499-514

[11] Eggertsen G, Lind P, Sj?quist J. Molecular characterization of the complement activating protein in the venom of the indian cobra (Naja n. siamensis). Mol Immunol, 1981, 18: 125-33

[12] Takahashi H, Hayashi K. Purification and characterzation of anticomplement factor (cobra venom factor) from the Naja naja atra venom. Biochim Biophys Acta, 1982, 701: 102-10

[13] Vogel CW, Müller-Eberhard HJ. Cobra venom factor: improved method for purification and biochemical characterization. J Immunol Methods, 1984, 73: 203-20

[14] Sun QY, Lu QM, Wang WY, et al. A highly active anticomplement factor from the venom of Naja kaouthia. Acta Biochem Biophy Sin, 2001, 33: 483-8

[15] Vogel CW, Bredehorst R, Fritzinger DC, et al. Structure and function of cobra venom factor, the complement- activating protein in cobra venom. Adv Exp Med Biol, 1996, 391: 97-114

[16] Vogel CW, Fritzinger DC. Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon, 2010, 56: 1198-222

[17] Liszewski MK, Farries TC, Lublin DM, et al. Control of the complement system. Adv Immunol, 1996, 61: 201-83

[18] Janssen BJ, Gomes L, Koning RI, et al. Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex. EMBO J, 2009, 28: 2469-78

[19] Laursen NS, Andersen KR, Braren I, et al. Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J, 2011, 30: 606- 16

[20] Botto M, Kirschfink M, Macor P, et al. Complement in human diseases: lessons from complement deficiencies. Mol Immunol, 2009, 46: 2774-83

[21] Takano T, Elimam H, Cybulsky AV. Complement - mediated cellular injury. Semin Nephrol, 2013, 33: 586- 601

[22] Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med, 2013, 24: 496-502

[23] Song WC. Crosstalk between complement and toll-like receptors. Toxicol Pathol, 2012, 40: 174-82

[24] Ricklin D, Lambris JD. Progress and trends in complement therapeutics. Adv Exp Med Biol, 2013, 735: 1-22

[25] Wang Cai'e, Sun Qianyun, Li Min, wait. Snake venom anti-complement protein atrase B inhibition Platelet aggregation induced by complement activation. Chinese Pharmacological Bulletin, 2 009, 25: 1205-9

[26] Li Min, Shen Liangxian, Zhang Xiangyan, wait. Two anti-complement proteins cause lipopolysaccharide Comparative study on the protective effect of acute lung injury. Chinese Pharmacological Bulletin, 2012, 28: 521-6

[27] Sun Qianyun, Li Min, Ye Qiaoling, wait. Activation of the complement alternative pathway leads to endothelial cell activation and damage. Chinese Pharmacological Bulletin, 2012, 28: 925-9

[28] Li Hongling, Sun Qianyun, Li Min, wait. Complement alternative pathway activation products stimulate endothelium cellular NF -κB, p38 MAPK, JAK 2 pathway activation and inhibitors intervention research. Chinese Journal of Cell Biology, 201 3, 35: 836-41

[29] Li Min, Sun Qianyun, Zhao Qiong, wait. Excessive activation of complement alternative pathway affects coagulation in vivo blood function. Chinese Pharmacological Bulletin, 2014, 30: 39-44

[30] Lu Qingyu, Li Min, Sun Qianyun. Activation of complement alternative pathway induces endothelial cell fibrinolysis Research on expression changes and intervention of coagulation-related molecules. Chinese Pharmacological Bulletin, 2015, 31: 1142-6

[31] O’Connell PJ, Cunningham A, d’Apice AJ. Xenotrans- plantation: its problems and potential as a clinical procedure. Transplant Rev, 2000, 14: 18-40

[32] Cooper DK, Ekser B, Tector AJ. Immunobiological barriers to xenotransplantation. Int J Surg, 2015 [Epub ahead of print]

[33] Leventhal JR, Dalma s so AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation, 1993, 55: 857-65

[34] Kobayashi T, Taniguchi S, Neethling FA, et al. Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy. Transplantation, 1997, 64: 1255-61

[35] Sun QY, Chen G, Guo H, et al. Prolonged cardiac xenograft survival in guinea pig-to-rat model by a highly active cobra venom factor. Toxicon, 2003, 42: 257-62

[36] Chen G, Sun QY, Wang XM, et al. Improved suppression of circulation complement dose not block acute vascular rejection of pig-to-rhesus monkey cardiac transplants. Xenotransplantation, 2004, 11: 123-32

[37] Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation, 2012, 93: 1-10

[38] Valenzuela NM, McNamara JT, Reed EF. Antibody- mediated graft injury: complement-dependent and complement-independent mechanisms. Curr Opin Organ Transplant, 2014, 19: 33-40

[39] Baldwin ΙΙΙ WM, Samaniego M, Qian ZP, et al. Complement as a mediator of allograft injury: an inflammatory view. Transplant Rev, 2000, 14: 41-51

[40] Chen S, Zhong S, Xiang Y, et al. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am J Transplant, 2011, 11: 2057-66

[41] Rutkowski MJ, Sughrue ME, Kane AJ, et al. Cancer and the complement cascade. Mol Cancer Res, 2010, 8: 1453-65

[42] Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol, 2013, 190: 3831-8

[43] Markiewski MM, Lambris JD. Is complement good or bad for cancer patients?A new perspective on an old dilemma. Trends Immunol, 2009, 30: 286-92

[44] Stevenson GT. Three major uncertainties in the antibody therapy of cancer. Haematologica, 2014, 99: 1538-46

[45] Nitta H, Murakami Y, Wada Y, et al. Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncol Rep, 2014, 32: 1715-9

[46] Downs-Canner S, Magge D, Ravindranathan R, et al. Complement inhibition: a novel form of immunotherapy for colon cancer. Ann Surg Oncol, 2015 [Epub ahead of print]

[47] Vogel CW, Müller-Eberhard HJ. Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/ C5 convertase. Proc Natl Acad Sci USA, 1981, 78: 7707-11

[48] Juhl H, Sievers M, BaltzerK, et al. A monoclonal antibody- cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach. Cancer Res, 1995, 55: 5749s-55s

[49] Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood, 2014, 124: 2804-11

[50] DeZ ern AE, Brod sky RA. Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia. Hematol Oncol Clin NorthAm, 2015, 29: 479-94

[51] Red blood cell diseases (anemia) group of the Hematology Branch of the Chinese Medical Association. Paroxysmal Chinese expert consensus on diagnosis and treatment of nocturnal hemoglobinuria. China Journal of Hematology, 2013, 34: 276-9

[52] Preis M, Lowrey CH. Laboratory tests for paroxysmal nocturnal hemoglobinuria. Am J Hematol, 2014, 89: 339-41

[53] Sun Qianyun, Ye Qiaoling, Yan Yinping. Mouse serum complement alternative pathway hemolysis New methods for activity determination. Chinese Pharmacological Bulletin, 2011, 27: 1619-22

[54] Vogel CW, Finnegan PW, Fritzinger DC. Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models. Mol Immunol, 2014, 61: 191-203

[55] Vogel CW, FritzingerDC, Gorsuch WB, et al. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases. Thromb Haemost, 2015, 113: 548-52